A brief overview of SARS-CoV-2 infection and its management strategies: a recent update 2023, Das et al

Sly Saint

Senior Member (Voting Rights)
Abstract


The COVID-19 pandemic has become a global health crisis, inflicting substantial morbidity and mortality worldwide. A diverse range of symptoms, including fever, cough, dyspnea, and fatigue, characterizes COVID-19. A cytokine surge can exacerbate the disease’s severity.

This phenomenon involves an increased immune response, marked by the excessive release of inflammatory cytokines like IL-6, IL-8, TNF-α, and IFNγ, leading to tissue damage and organ dysfunction. Efforts to reduce the cytokine surge and its associated complications have garnered significant attention. Standardized management protocols have incorporated treatment strategies, with corticosteroids, chloroquine, and intravenous immunoglobulin taking the forefront. The recent therapeutic intervention has also assisted in novel strategies like repurposing existing medications and the utilization of in vitro drug screening methods to choose effective molecules against viral infections.

Beyond acute management, the significance of comprehensive post-COVID-19 management strategies, like remedial measures including nutritional guidance, multidisciplinary care, and follow-up, has become increasingly evident. As the understanding of COVID-19 pathogenesis deepens, it is becoming increasingly evident that a tailored approach to therapy is imperative.

This review focuses on effective treatment measures aimed at mitigating COVID-19 severity and highlights the significance of comprehensive COVID-19 management strategies that show promise in the battle against COVID-19.

https://link.springer.com/article/10.1007/s11010-023-04848-3

Strategies for post-COVID management
Since well-designed randomized controlled trials are lacking for post-viral infections, it is challenging to develop an evidence-based approach for its therapy. Post-viral tiredness that lasts longer than six months may qualify as chronic fatigue syndrome or myalgic encephalomyelitis (ME) [post-COVID fatigue. Prog Neurol Psychiatry 25:36–39. https://doi.org/10.1002/pnp.698 " href="https://link.springer.com/article/10.1007/s11010-023-04848-3#ref-CR109" id="ref-link-section-d507086550e1153">109]. Since post-viral infection is a milder version of chronic fatigue syndrome (ME/CFS), it stands to reason that the same approaches used to treat ME/CFS might also be effective in treating post-viral infections.
 
As the understanding of COVID-19 pathogenesis deepens, it is becoming increasingly evident that a tailored approach to therapy is imperative.

Not evident to me.
 
Since post-viral infection is a milder version of chronic fatigue syndrome (ME/CFS), it stands to reason that the same approaches used to treat ME/CFS might also be effective in treating post-viral infections.
Too bad we don't have any effective ones. Only had decades, couldn't be bothered to try.
 
Back
Top Bottom